These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 15353829)
21. In percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy, it is not the speed of intracoronary alcohol injection but the amount of alcohol injected that determines the resultant infarct size. Cheng TO Circulation; 2004 Jul; 110(3):e23; author reply e23. PubMed ID: 15262858 [No Abstract] [Full Text] [Related]
22. Serial septal branch assessment in hypertrophic obstructive cardiomyopathy: New echocardiographic contrast agent for alcohol septal ablation. Rigopoulos AG; Pfeiffer B; Seggewiss H Herz; 2014 Mar; 39(2):219-21. PubMed ID: 23588605 [No Abstract] [Full Text] [Related]
23. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Jassal DS; Neilan TG; Fifer MA; Palacios IF; Lowry PA; Vlahakes GJ; Picard MH; Yoerger DM Eur Heart J; 2006 Aug; 27(15):1805-10. PubMed ID: 16774986 [TBL] [Abstract][Full Text] [Related]
24. Myectomy for hypertrophic obstructive cardiomyopathy after failed alcohol septal ablation: clinicopathological correlations. Arrazaghi AA; Butany JW; Williams WG; Wigle DE; Rakowski H Can J Cardiol; 2001 Feb; 17(2):197-202. PubMed ID: 11223490 [TBL] [Abstract][Full Text] [Related]
25. Hemodynamic rounds series II: hemodynamic effects of alcohol-induced septal infarction for hypertrophic obstructive cardiomyopathy. Kern MJ; Rajjoub H; Bach R Catheter Cardiovasc Interv; 1999 Jun; 47(2):221-8. PubMed ID: 10376511 [No Abstract] [Full Text] [Related]
26. Choice of Septal Reduction Therapies and Alcohol Septal Ablation. Fifer MA Cardiol Clin; 2019 Feb; 37(1):83-93. PubMed ID: 30447719 [TBL] [Abstract][Full Text] [Related]
27. Microvascular obstruction after nonsurgical septal reduction for the treatment of hypertrophic cardiomyopathy. Wu KC; Heldman AW; Brinker JA; Hare JM; Lima JA Circulation; 2001 Oct; 104(15):1868. PubMed ID: 11591628 [No Abstract] [Full Text] [Related]
29. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692 [TBL] [Abstract][Full Text] [Related]
30. Inferior infarction following alcohol septal ablation: a consequence of "collateral damage"? Chowdhary S; Galiwango P; Woo A; Schwartz L Catheter Cardiovasc Interv; 2007 Feb; 69(2):236-42. PubMed ID: 17195204 [TBL] [Abstract][Full Text] [Related]
31. Commentary and re-appraisal: surgical septal myectomy vs. alcohol ablation: after a decade of controversy and mismatch between clinical practice and guidelines. Maron BJ Prog Cardiovasc Dis; 2012; 54(6):523-8. PubMed ID: 22687595 [No Abstract] [Full Text] [Related]
32. Conservative management of complete heart block complicating percutaneous transluminal septal myocardial ablation for patients with obstructive hypertrophic cardiomyopathy. Cheng TO Am J Cardiol; 2004 Oct; 94(7):982. PubMed ID: 15464700 [No Abstract] [Full Text] [Related]
33. Contrast echocardiography during alcohol septal ablation: friend or foe? Alfonso F; Isla LP; Seggewiss H Heart; 2005 Feb; 91(2):e18. PubMed ID: 15657208 [No Abstract] [Full Text] [Related]
34. Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. Rigopoulos AG; Seggewiss H Curr Cardiol Rev; 2016; 12(4):285-296. PubMed ID: 25563291 [TBL] [Abstract][Full Text] [Related]
35. [Effectivness of transcatheter alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy]. Chernov SA; Kucherov VV; Fursov AN; Zakharova EG; Gaĭdukov AV; Liapkova NB; Korneev NV; Pestovskaia OR Voen Med Zh; 2009 Feb; 330(2):28-35. PubMed ID: 19351021 [No Abstract] [Full Text] [Related]
36. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. van der Lee C; Scholzel B; ten Berg JM; Geleijnse ML; Idzerda HH; van Domburg RT; Vletter WB; Serruys PW; ten Cate FJ Am J Cardiol; 2008 May; 101(9):1315-20. PubMed ID: 18435964 [TBL] [Abstract][Full Text] [Related]